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Abstract 
Objective: We conducted a retrospective cohort study to assess the effect of tracking People Living with HIV (PLHIV) 
after missed clinic visits and factors associated with return to care in rural Uganda. We assessed retention in care 
among 650 HIV‑infected women and men. We used univariable and multivariable generalized linear models to assess 
demographic and self‑reported factors associated with re‑engagement in HIV care.
Results: Of 381 PLHIV who ever missed a scheduled appointment, 68% were female and most (80%) had initi‑
ated ART. Most (70%) of those tracked returned to care. Relative to men, women (adjusted risk ratio [ARR] 1.23; 95% 
confidence interval (CI) 1.05–1.43; p = 0.009) were more likely to return to care after active tracking. PLHIV who missed 
scheduled visits for other reasons (forgetting, adequate drug supplies, or long distance to clinic) had reduced odds of 
return to care (ARR 0.41; 95% CI 0.28–0.59; p < 0.001). These data support close monitoring of patient retention in HIV 
care and active measures to re‑engage those who miss an appointment. Furthermore, they highlight the need for 
targeted interventions to those more resistant to re‑engagement such as men.
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Introduction
Uganda is one of 15 countries that accounted for 75% of 
the 2.1 million new HIV infections that occurred in 2015 
[1]. Uganda has scaled up coverage of antiretroviral ther-
apy (ART), which durably suppresses plasma and geni-
tal tract viral load, decreases HIV-associated mortality, 
and prevents HIV transmission [2, 3]. The proportion of 
HIV-infected adults receiving ART in Uganda increased 
from an estimated 37–57% in 2011 to 81% in 2016/2017 
[4]. Increased ART coverage was accompanied by a 51% 
decrease in the number of new HIV infections and a 45% 
reduction in HIV-related mortality between 2010 and 
2016 [5].
Patient retention in HIV care is key to achieving Joint 
United Nations Programme on HIV/AIDS (UNAIDS) 
and national 90-90-90 targets: 90% of all people with 
HIV to be diagnosed and know their status, 90% of all 
HIV-infected people to receive ART, and 90% of per-
sons receiving ART to be virally suppressed by 2020 [6, 
7]. Continuous engagement with the healthcare system 
by HIV infected individuals is a key challenge for HIV 
treatment programs [8]; losses occur at each step of the 
HIV care cascade [9], and most attrition occurs during 
the first 24 months of ART [10]. Despite the personal and 
public health benefits of HIV treatment, global retention 
in care on ART at 12 months was approximately 74% in 
2016 [11]. In Uganda, attrition rates of up to 20% have 
been reported 12 months after ART initiation [12].
Persons not retained in care experience treatment 
interruptions and viral non-suppression, which increases 
risk of drug resistant virus, and compromises personal 
and population-level benefits of ART [11]. Although 
no uniform definition of retention in care exists, at 
least one visit to an HIV care provider every 6  months 
is typically used to allow for clinically stable and viro-
logically suppressed PLHIV who require fewer provider 
interactions [13–17]. Strategies to improve retention 
in HIV care include peer support, targeted counselling, 
mobile phone tracking and home visits [13]. Targeted 
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retention interventions could minimize ART interrup-
tions and reduce HIV-related morbidity and mortality 
[11]. We undertook a study at a rural government hos-
pital in North-Eastern Uganda, with specific challenges 
of an agro-pastoralist community which practices semi-
nomadic livestock rearing and whose settlement pat-
terns are determined by availability of pasture and water 
sources [18]. We assessed the effect of patient tracking 
using phone calls and/or home visits on return to care 
among PLHIV who missed their scheduled visits.
Main text
Methods
Population and procedures
Between January 2014 and August 2015, we conducted a 
retrospective cohort study of PLHIV receiving HIV care 
at Moroto Regional Referral Hospital (RRH). The HIV 
program at this facility was supported by the Civil Soci-
ety Fund Regional Referral Hospitals Project [19]. We 
included in the study PLHIV who enrolled in the ART 
clinic during the study period, missed a scheduled visit, 
and had medical records in the Open Medical Records 
System  (OpenMRS®) database. Those who missed a 
scheduled clinic visit were contacted by telephone after 
5 days (Fig. 1). The clinic had a designated counsellor to 
actively track persons who missed one or more visits. If 
the PLHIV had no telephone contact or failed to return to 
the clinic after several calls, a home visit was conducted by 
clinic staff, an expert client or a peer leader. PLHIV were 
tracked for 3  consecutive months after a missed sched-
uled visit. Those who did not return were flagged as lost to 
follow-up. These active tracking measures were intended 
to encourage PLHIV to return to active follow-up, address 
psychosocial issues and better understand circumstances 
that led to failure to turn up for the scheduled clinic visit. 
Data on PLHIV age, gender, ART status, tracking method, 
return to clinic, and reason(s) for missed visits were col-
lected on PLHIV tracking/follow-up forms.
Statistical analysis
Return to care (the primary outcome) was defined as return 
to care within 3 months of being tracked. Descriptive sta-
tistics and frequency distributions were performed for 
continuous and categorical data, respectively. To identify 
factors associated with returning to care after active track-
ing, we categorized PLHIV who were tracked after missing 
an appointment by whether they did or did not return to 
care. A generalized linear model was used to estimate risk 
ratios of return to care after adjusting for underlying differ-
ences in predictor variables (age, gender, ART status, mode 
of contact and reason(s) for missing scheduled clinic visit). 
Significance was set at p < 0.05. Data were analyzed using 
Stata version 14 (StataCorp LLC, College Station, Texas).
Results
Of the 650 persons in HIV care during the study period, 
381 (59%) had ever missed a scheduled clinic visit and 
were included in the present analysis. For these 381, 
the median age was 30 years [interquartile range (IQR), 
23–35], 259 (68%) were female and 306 (80%) had initi-
ated ART (Table  1). Overall, 598 phone calls and 472 
home visits were conducted during the study period.
Seventy percent of PLHIV tracked by phone call and/or 
home visits returned to care. Of these, 74% were women. 
PLHIV were as likely to return to care after being tracked 
through a phone call as through home visit (73% vs. 64%; 
p = 0.08). Of the 42% who self-reported missing sched-
uled clinic visits because of having travelled away from 
home, most (67%) were women. Forty-three percent 
reported socio-structural barriers to retention in care 
including forgetting the scheduled appointment, long 
distance to clinic, tight work schedules, stigma, ART side 
effects, having adequate supplies of drugs, and lack of 
food. The remaining 15% were unreachable or not avail-
able when tracked by phone and/or home visit.
In multivariable analyses, women were more likely to 
return to care after active tracking than men (adjusted 
risk ratio [ARR] 1.23; 95% CI 1.05–1.43; p = 0.009). Com-
pared with persons who had travelled, those who were 
unavailable/unreachable at time of contact (ARR 0.85; 
95% CI 0.75–0.95; p = 0.01) and those that reported other 
reasons for missing their scheduled appointments e.g., 
long distance to clinic, stigma, still having drug supplies 
Fig. 1 PLHIV contact (phone call and/or home visit) flow diagram. 
PC, phone call; HV, home visit; C, contacted; NC, not contacted; R, 
returned; NR, not returned; LTFU, lost to follow up
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or forgetting the appointment (ARR 0.41; 95% CI 0.28–
0.59; p < 0.001) were less likely to return to care after 
missing a scheduled visit. Age, ART status and tracking 
method were not related to return to care (p = 0.27, 0.12 
and 0.83, respectively).
Discussion
In this retrospective cohort study of HIV-infected Ugan-
dan adults, in which PLHIV who missed scheduled vis-
its were actively followed through phone contact and/or 
home visits, most returned to care after being tracked. 
Female gender and prior receipt of ART were predic-
tors of return to HIV care. Those who reported non-
travel reasons for missed visits, or were unreachable by 
designated personnel, were significantly less likely to be 
retained in HIV care.
We found that women and PLHIV on ART were more 
likely to return to HIV care after missing a scheduled 
clinic visit. This finding is in agreement with prior stud-
ies in which gender and ART status were associated with 
return to care after tracking [16, 20–22]. In a systematic 
review of 42 studies from 12 countries, factors associ-
ated with lower retention rates included younger age, 
male gender, stigma, non-disclosure of HIV status, fear of 
drug side effects, and transport costs [23]. Other studies 
have found that denial of HIV status, healthy status per-
ception, substance use, mental illness, distrust of medi-
cal providers, and side effects of HIV medications were 
associated with poorer retention [14, 23, 24]. Address-
ing these factors could increase the likelihood of staying 
engaged and retained in HIV care. In our study, a sig-
nificantly higher proportion of men did not re-engage in 
care after active tracking. In East and Southern Africa, 
ART coverage is lower among men than women (57% vs 
72%) [25], and men are less likely than women to adhere 
to HIV treatment resulting in poorer outcomes [26, 
27]. Cultural constructs of masculinity and HIV stigma 
appear to influence health seeking behavior and com-
promise HIV care utilization in this setting [27]. HIV 
providers should utilize culturally appropriate initiatives 
to encourage health-enabling masculinities and support 
retention in care.
The proportion of PLHIV who ever missed a scheduled 
clinic visit in our study is similar to that reported in other 
studies of mobile populations [15, 16, 22]. Some PLHIV 
may have cycled in and out of care, given the mobile 
nature of the study population [9]. We observed that 
most PLHIV who were traced re-engaged in HIV care. 
Active tracing and linkage to care likely account for these 
findings. Monitoring retention on ART is key to estimat-
ing the proportion disengaging from care and developing 
targeted interventions to improve engagement in care, 
decreasing mortality, and minimizing adverse treatment 
outcomes [11]. Ancillary services such as case manage-
ment, outreach, support groups, and patient navigation 
could further improve retention in care and facilitate 
attainment of national and global HIV treatment goals 
[28–33].
In our study, clinical, structural and psychosocial bar-
riers to retention in care included long distance travel 
to clinic, tight work schedules, stigma, ART side effects, 
forgetting the scheduled appointment and food inse-
curity. This study was undertaken in Karamoja region. 
The region has poorer health outcomes than elsewhere 
Table 1 Distribution of  patient characteristics stratified by  return to  HIV care and  predictors of  return to  care having 
missed a scheduled appointment after tracking
Characteristic N (%) or median (IQR) Did not return to HIV 
care (n = 114)
Returned to HIV 
care (n = 267)
p-value Adjusted OR (95% CI) p-value
Age in years, median (IQR) 30 (25–36) 29 (22–34) 0.01 0.99 (0.98–1.01) 0.265
Gender
 Male 53 (43.4) 69 (56.6) < 0.001 Reference
 Female 61 (23.5) 198 (76.5) 1.23 (1.05–1.43) 0.009
ART status
 ART naive 33 (44.0) 42 (56.0) 0.003 Reference
 On ART 81 (26.5) 225 (73.5) 1.16 (0.96–1.39) 0.119
Tracking method
 Phone call 63 (26.7) 173 (73.3) 0.08 Reference
 Home visit 51 (35.2) 94 (64.8) 0.98 (0.87–1.11) 0.832
Reason for missing appointment
 Travelled 51 (31.5) 111 (68.5) < 0.001 Reference
 Unavailable 38 (67.9) 18 (32.1) 0.85 (0.75–0.95) 0.006
 Other 25 (15.3) 138 (84.7) 0.41 (0.28–0.59) < 0.001
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in Uganda due to a combination of environmental, geo-
graphical, economic and cultural issues leading to con-
flict, food insecurity and malnutrition, high alcohol rates, 
gender based violence and low education rates [34]. 
Despite these difficulties, our findings are in striking 
agreement with other work from sub-Saharan Africa in 
which 65% reported structural barriers (transportation, 
distance to clinic, poverty), 33% reported clinic-based 
barriers (long waiting times), and 27% reported psycho-
social barriers (social support, stigma and non-disclosure 
of HIV status) to retention in care [35]. These socio-
structural factors are major determinants of retention in 
HIV care [36]. Accessing HIV care closer to home may 
decrease the cost and disruption of ART non-adherence. 
Community-based ART delivery programs, in which 
ART is delivered to consenting, stable participants at 
community drug distribution points, improve access to 
HIV treatment services, ART adherence and retention 
in care in resource-limited settings [37]. This alternative 
delivery model provides drug refills every 2–3  months, 
decreases waiting times, reduces travel time and costs, 
and provides psychosocial support by expert clients, 
thereby reducing the impact of socio-structural barri-
ers on retention in care [37]. Community drug distribu-
tion points are an effective alternative delivery model 
which should be scaled up to improve retention in care in 
resource-limited settings.
Conclusion
In conclusion, we found that nearly half of HIV-infected 
adults attending a rural HIV clinic in a region with 
poor health outcomes had ever missed a scheduled 
visit. Seven-in-ten PLHIV returned to HIV care follow-
ing active tracing using home visits and phone calls. 
These data support active monitoring of patient reten-
tion in ART care and highlight the need for targeted 
interventions to engage men and others who struggle to 
maintain engagement in care especially in challenging 
environments.
Limitations
Our study has limitations. We did not collect mortal-
ity data and those who returned to care may have been 
more likely to be healthy. Data were collected from a 
public sector clinic and there were considerable miss-
ing data. We did not evaluate socio-economic variables 
including level of education, occupation, marital status 
and disclosure of HIV status because these data are not 
routinely collected. Finally, we did not document CD4 
counts, HIV viral load, and ART regimen to objectively 
assess HIV treatment outcomes after return to care. 
These factors may limit the generalizability of our find-
ings. Nevertheless, we demonstrated that a substantial 
proportion of PLHIV re-engaged in HIV care following 
active tracing in a rural, resource-limited ART clinic.
Abbreviations
HIV: human immunodeficiency virus; PLHIV: people living with human 
immunodeficiency virus; ARR : adjusted risk ratio; CI: confidence interval; ART 
: antiretroviral therapy; UNAIDS: United Nations Programme on HIV/AIDS; RRF: 
Regional Referral Hospital; CSF: Civil Society Fund.
Authors’ contributions
DAB and RPR designed the intervention. MSN and RPR designed the 
retrospective study. MSN and AM wrote the first draft. MSN performed the 
statistical analyses. RK edited and assisted in the writing of second draft. AK 
supervised the statistical analysis and edited the subsequent drafts of the 
manuscript. BC edited and assisted in the writing of the manuscript various 
drafts. IO collected the data and also drafted the manuscript. LN contacted 
the study participants and helped with the proof reading of the manuscript. 
All authors contributed to data collection, interpretation of the results and the 
writing of the manuscript, and all approved the final draft. All authors read and 
approved the final manuscript.
Author details
1 Infectious Diseases Institute, College of Health Sciences, Makerere University, 
Kampala, Uganda. 2 Cambridge Institute of Public Health, University of Cam‑
bridge, Cambridge, UK. 3 Department of Epidemiology and Biostatistics, 
College of Health Sciences, Makerere University, Kampala, Uganda. 
Acknowledgements
We thank study participants for their invaluable contributions. We thank the 
management and staff of Moroto Regional Referral Hospital for assistance 
with data collection.
These data were reported, in part, at the 2nd Edition UNESCO‑MERCK 
Africa Research Summit (UNESCO‑MARS), 28–29th November 2016, Addis 
Ababa, Ethiopia (poster abstract).
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The dataset used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Consent for publication
Not applicable.
Ethics statement
Ethical approval for this study was granted by the Joint Clinical Research 
Center Institutional Review Board and the Uganda National Council for Sci‑
ence and Technology (HS 1631). Due to the retrospective study design and 
strict anonymity of participants, the need for patient consent was waived by 
UNCST.
Funding source
This work was supported by a Civil Society Fund grant to the Infectious 
Diseases Institute (Grant CSF #01‑10‑003). Support for manuscript writing was 
provided by the Fogarty International Center, National Institutes of Health 
(Grant #D43 TW009771 “HIV co‑infections in Uganda: TB, Cryptococcus, and 
Viral Hepatitis” and Grant #K43 TW010695 [to AM]).
Role of the funding source The authors designed and executed the 
study, had full access to the raw data, performed all analyses, wrote the manu‑
script, and had final responsibility for the decision to submit for publication. 
The funder had no role in design, data collection, analysis, interpretation, or 
writing of the report.
Page 5 of 5Nabaggala et al. BMC Res Notes          (2018) 11:762 
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 31 August 2018   Accepted: 17 October 2018
References
 1. WHO. Progress report 2016: prevent HIV, test and treat all: WHO support 
for country impact. 2016. http://www.who.int/iris/handl e/10665 /25171 3. 
Accessed 3 July 2018.
 2. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. 
Initiation of antiretroviral therapy in early asymptomatic HIV infection. N 
Engl J Med. 2015;373(9):795–807.
 3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumar‑
asamy N, et al. Antiretroviral therapy for the prevention of HIV‑1 transmis‑
sion. N Engl J Med. 2016;375(9):830–9.
 4. WHO. Global update on HIV treatment 2013: results, impact and opportu‑
nities. 2013.
 5. UNAIDS. Uganda Country Factsheet. 2017 [Internet]. Available 
from: http://www.unaid s.org/en/regio nscou ntrie s/count ries/ugand a. 
Accessed 2 July 2018.
 6. UNAIDS. Joint United Nations Programme on HIV/AIDS. 90‑90‑90: an 
ambitious treatment target to help end the AIDS epidemic. 2014.
 7. Uganda Ministry of Health. UAC. National HIV and AIDS Strategic Plan 
2015/2016–2019/2020 [Internet]. Available from:  http://libra ry.healt h.go.
ug/publi catio ns/servi ce‑deliv ery‑disea ses‑contr ol‑preve ntion ‑commu 
nicab le‑disea ses/hivai ds/natio nal‑h‑1. Accessed 23 June 2018.
 8. Rachlis B, Bakoyannis G, Easterbrook P, Genberg B, Braithwaite RS, Cohen 
CR,  Bukusi EA, Kambugu A, Bwana MB, Somi GR, Geng EH. Facility‑level 
factors influencing retention of patients in HIV care in East Africa. PloS 
one. 2016 Aug 10;11(8):e0159994.
 9. Kranzer K, Govindasamy D, Ford N, Johnston V, Lawn SD. Quantifying and 
addressing losses along the continuum of care for people living with 
HIV infection in sub‑Saharan Africa: a systematic review. J Int AIDS Soc. 
2012;15(2):17383.
 10. Hassan AS, Mwaringa SM, Ndirangu KK, Sanders EJ, de Wit TF, Berkley 
JA. Incidence and predictors of attrition from antiretroviral care among 
adults in a rural HIV clinic in Coastal Kenya: a retrospective cohort study. 
BMC Public Health. 2015;15:478.
 11. WHO. Global report on early warning indicators of HIV drug resistance: 
technical report 2016.
 12. WHO. Retention in HIV Programmes. Defining the challenges and 
identifying solutions. Meeting report 13–15 September 2011 [Internet]. 
Available from:  https ://whqli bdoc.who.int/publi catio ns/2012/97892 
41503 686_eng.pdf. Accessed 2 Sept 2018.
 13. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in 
medical care among HIV‑diagnosed persons: a meta‑analysis. AIDS. 
2010;24(17):2665–78.
 14. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engage‑
ment in HIV care in the United States: from cascade to continuum to 
control. Clin Infect Dis. 2013;57(8):1164–71.
 15. Mugavero MJ, Davila JA, Nevin CR, Giordano TP. From access to engage‑
ment: measuring retention in outpatient HIV clinical care. AIDS Patient 
Care STDS. 2010;24(10):607–13.
 16. Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, et al. 
Missed visits and mortality among patients establishing initial outpatient 
HIV treatment. Clin Infect Dis. 2009;48(2):248–56.
 17. Horstmann E, Brown J, Islam F, Buck J, Agins BD. Retaining HIV‑infected 
patients in care: where are we? Where do we go from here? Clin Infect 
Dis. 2010;50(5):752–61.
 18. UNDP. KARAMOJA: MOROTO district, hazard, risk and vulnerability profile. 
2014. http://www.ug.undp.org/conte nt/ugand a/en/home/libra ry/crisi 
s_preve ntion _and_recov ery/karam oja–morot o‑distr ict–hazar d–risk‑and‑
vulne rabil ity‑profi l.html.
 19. Infectious Diseases Institute. Annual Report. 2012. Investing in the 
future:Impacting Real Lives [Internet]. Available from: https ://www.
idi‑maker ere.com/wp‑conte nt/uploa ds/2017/08/IDI‑Annua l‑Repor 
t‑2012.pdf. Accessed 9 Sept 2018.
 20. Cunningham CO, Buck J, Shaw FM, Spiegel LS, Heo M, Agins BD. Fac‑
tors associated with returning to HIV care after a gap in care in New 
York State. Journal of acquired immune deficiency syndromes (1999). 
2014;66(4):419.
 21. Cabral HJ, Tobias C, Rajabiun S, Sohler N, Cunningham C, Wong M, et al. 
Outreach program contacts: do they increase the likelihood of engage‑
ment and retention in HIV primary care for hard‑to‑reach patients? AIDS 
Patient Care STDS. 2007;21(Suppl 1):S59–67.
 22. Nakigozi G, Makumbi FE, Kigozi G, Nalugoda F, Reynolds SJ, Chang LW, 
et al. Barriers to utilization of HIV care services among adolescents and 
young adults in Rakai, Uganda: the role of economic strengthening. 
Global Soc Welfare. 2015;2(2):105–10.
 23. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators 
for linkage to antiretroviral therapy care: a systematic review. AIDS. 
2012;26(16):2059–67.
 24. Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR. 
Case management is associated with improved antiretroviral adherence 
and CD4 + cell counts in homeless and marginally housed individuals 
with HIV infection. Clin Infect Dis. 2006;43(2):234–42.
 25. UNAIDS. Miles to go—closing gaps, breaking barriers, righting injustices. 
2018. http://www.unaid s.org/sites /defau lt/files /media _asset /miles 
‑to‑go_en.pdf.
 26. Koole O, Tsui S, Wabwire‐Mangen F, Kwesigabo G, Menten J, Mulenga M, 
Auld A, Agolory S, Mukadi YD, Colebunders R, Bangsberg DR. Retention 
and risk factors for attrition among adults in antiretroviral treatment 
programmes in Tanzania, Uganda and Zambia. Tropi Med Int Health. 
2014;19(12):1397–410.
 27. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our 
blind spot. Trop Med Int Health. 2011;16(7):828–9.
 28. Messeri PA, Abramson DM, Aidala AA, Lee F, Lee G. The impact of ancillary 
HIV services on engagement in medical care in New York City. AIDS Care. 
2002;14(Suppl 1):S15–29.
 29. Rothman J, Rudnick D, Slifer M, Agins B, Heiner K, Birkhead G. Co‑located 
substance use treatment and HIV prevention and primary care services, 
New York State, 1990–2002: a model for effective service delivery to a 
high‑risk population. J Urban Health. 2007;84(2):226–42.
 30. French T, Tesoriero J, Agins B. Changes in stress, substance use and 
medication beliefs are associated with changes in adherence to HIV 
antiretroviral therapy. AIDS Behav. 2011;15(7):1416–28.
 31. French T, Weiss L, Waters M, Tesoriero J, Finkelstein R, Agins B. Correlation 
of a brief perceived stress measure with nonadherence to antiretroviral 
therapy over time. J Acquir Immune Defic Syndr. 2005;38(5):590–7.
 32. Sitapati AM, Limneos J, Bonet‑Vazquez M, Mar‑Tang M, Qin H, Mathews 
WC. Retention: building a patient‑centered medical home in HIV primary 
care through PUFF (Patients Unable to Follow‑up Found). J Health Care 
Poor Underserved. 2012;23(3 Suppl):81–95.
 33. Gross R, Bellamy SL, Chapman J, Han X, O’Duor J, Palmer SC, et al. Man‑
aged problem solving for antiretroviral therapy adherence: a randomized 
trial. JAMA Intern Med. 2013;173(4):300–6.
 34. USAID. CLIMATE RISK SCREENING FOR FOOD SECURITY KARAMOJA 
REGION, UGANDA. 2017. https ://www.usaid .gov/sites /defau lt/files /
docum ents/1866/17013 0_Karam oja_Food_Secur ity_Clima te_Scree ning.
pdf.
 35. Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, 
et al. Retention in care among HIV‑infected patients in resource‑limited 
settings: emerging insights and new directions. Curr HIV/AIDS Rep. 
2010;7(4):234–44.
 36. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, 
Yiannoutsos CT, et al. Understanding reasons for and outcomes of 
patients lost to follow‑up in antiretroviral therapy programs in Africa 
through a sampling‑based approach. J Acquir Immune Defic Syndr. 
2010;53(3):405–11.
 37. PEPFAR. Improving access to HIV treatment services through community 
ART distribution points in Uganda. Washington, D.C. PEPFAR; 2018. https 
://www.pepfa rsolu tions .org/women /2018/1/13/impro ving‑acces s‑to‑hiv‑
treat ment‑servi ces‑throu gh‑commu nity‑art‑distr ibuti on‑point s‑in‑ugand 
a.
